Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-521901-42-00
Authorised, recruiting Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

2025-521901-42-00 · tracked via the Priya Life Science EU tracker
Sponsor
Contineum Therapeutics Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
26/08/2026
Enrollment target
156
Sites
Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain

Condition studied

Idiopathic Pulmonary Fibrosis (IPF)

Investigational medicinal product(s)

PIPE-791Placebo to PIPE-791

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Change in FVC (mL) from Baseline to Week 26

Endpoint detail

•The percentage of subjects (%) with Treatment Emergent Adverse Events (TEAE), • Relative change in FVC (mL) from Baseline to Week 26, • Absolute change and relative change in percent predicted FVC (ppFVC) (%) from Baseline to Week 26, • Proportion of participants with a ≥ 10% absolute decline in ppFVC (%) at Week 12 and 26 from Baseline, • Time to first ≥ 10% absolute decline in ppFVC (%), • Change in quantitative CT-derived lung fibrosis burden on HRCT

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521901-42-00 on CTIS ↗ ← All trials in the EU